Evaluation of p16INK4a immunohistochemical reactivity in endocervical glandular neoplasia

Journal of Lower Genital Tract Disease

Volumn 15, Issue 1, 2011, Pages 1-5

  Monroe, Mänette ^a   Wilkinson, Edward J ^a   Butler, Samantha L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Endocervical adenocarcinoma; immunohistochemistry; p16INK4a

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EOSIN; HEMATOXYLIN;

ADENOCARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MEDICAL RECORD REVIEW; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; BIOSYNTHESIS; CYTOCHEMISTRY; EVALUATION; GENE EXPRESSION; METHODOLOGY; NEOPLASM; PATHOLOGY; UTERUS CANCER;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATHOLOGY; UTERINE NEOPLASMS;

EID: 78651353260     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3181f0b8da     Document Type: Article

References (24)

1. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carci-noma of the uterine cervix in the United States\a 24-year population based study. Gynecol Oncol 2000;78:97-105.
2. Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. BrJ Cancer 1999;81:159-66.
3. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000;86:429-35.
4. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357:1490-3.
5. Lee KR, Daragh TM, Joste NE, Krane JF, Sherman ME, Hurley LB, et al. Atypical glandular cells of undetermined sig-nificance (AGUS): interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol 2002;117:96-102.
6. Simsir A, Hwang S, Cangiarella J, Elgert P, Levine P, Sheffield MV, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and predic-tion of cell of origin. Cancer 2003;99:323-30.
7. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer 2003;99:336-41.
8. Young R H, Clement P B. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002;41:185-207.
9. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and micro-glandular hyperplasia. Histopathology 2002;41:313-21.
10. Kurman RJ, Norris HJ, Wilkinson E. Tumors of the cervix; glandular lesions. In: Rosai J, Sbin LH, eds. Tumors of the Cervix, Vagina and Vulva. Washington DC: Armed Forces Institute of Pathology; 1992;4:77-95.
11. Zielinski GD, Snijders PJ, RozendaalL, Daalmeijer NF, Risse EK, Voorhorst FJ, et al. The presence of high-risk HPV combined with specific p53 and p16 INK4a expression pat-terns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43.
12. McCluggage WG, Jenkins D. Immunohistochemical staining with p16 may assist in the distinction between endo-metrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-35.
13. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996;93:4350-4.
14. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry V, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
15. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2: 342-50.
16. Dray M, RussellP, Dalrymple C, Wallman N, Angus G, Leong A, et al. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix: I. Ex-perience with squamous lesions in 189 consecutive cervical biopsies. Pathology 2005;37:112-24.
17. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8-15.
18. Muller S, Flores-Staino C, Skyldberg B, Hellström AC, Johansson B, Hagmar B, et al. Expression of p16 and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. Int J Oncology 2008;32:333-40.
19. a overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch. 2006;448:597-603.
20. McCluggage WG. Immunohistochemistry as a diag-nostic aid in cervical pathology. Pathology 2007;39:97-111.
21. Sanati S, Huettner P, Yagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dys-plastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol 2010;29:79-87.
22. Carico E, Fulciniti F, Giovagnoli RM, Losito NS, Botti G, Benincasa G, et al. Adhesion molecules and p16 ex-pression in endocervical adenocarcinoma. Virchows Arch 2009:455:245-51.
23. INK4a immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarci-nomas in a tissue microarray study. Mod Pathol 2009;22: 797-806.
24. Crum CP, Lee KR. Diagnostic Gynecologic and Obste-tric Pathology. Philadelphia, PA: Elsevier Saunders; 2006:378.